Germans Trias i Pujol Research Institute (IGTP)

IGTP welcomes two new spin-offs: Debios Diagnostics and HealthTech Innovations The Germans Trias i Pujol Research Institute (IGTP) has welcomed two new spin-offs to its innovation ecosystem at the Can Ruti Campus: DEBIOS Dx and Healthtech Innovations SL. These ventures strengthen IGTP's commitment to technology transfer within the biomedical field. ◾ Debios Diagnostics specialises in non-invasive diagnostics for genitourinary diseases, developing solutions that enable early detection of complex conditions such as renal fibrosis. ◾ HealthTech Innovations focuses on enhancing operating room efficiency and safety through the integration of advanced technologies, including robotics, artificial intelligence, and virtual reality. Raül Zurita, head of IGTP's Innovation Unit, notes that the creation of these spin-offs "solidifies our commitment to innovation and technology transfer in the biomedical field. These spin-offs represent a significant step forward in the use of advanced technologies to address real clinical challenges, with the aim of improving both patient quality of life and healthcare system efficiency." These initiatives reflect IGTP's strategy of extending translational research beyond the laboratory, connecting science with society, and developing products that transform clinical practice. Learn more: https://lnkd.in/db4MGFzS #BiomedicalResearch #TechnologyTransfer #HealthcareInnovation #MedicalTechnology #ArtificialIntelligence #RoboticsInHealthcare #SpinOffs

🆕 IGTP and EATRIS strengthen ties with a symposium focused on driving translational research with patient involvement   Last Thursday, the Germans Trias i Pujol Research Institute (IGTP) held an event to share resources, perspectives, and advancements of EATRIS, the European infrastructure for translational medicine, with a special focus on patient involvement in biomedical research. It provided an opportunity for the research community at the Can Ruti Campus to explore the opportunities offered by being part of the IIS-IGTP, which was recently reaccredited by Instituto de Salud Carlos III (ISCIII) and is linked to EATRIS.   🗣️ Julia Garcia Prado noted that "these seminars and our collaboration with EATRIS ensure that our research and innovation projects have a European impact. We will continue to work in this direction to promote projects with high added value with and for our patients and society".   Read more: https://lnkd.in/dfWKpiek   #CampusCanRuti #PatientEngagement

👏 Congratulations to all the professionals awarded this year! #PremisExcellènciaCoMB2024 Among the 2024 awardees are three distinguished professionals from Hospital Universitari Germans Trias i Pujol. In the Medical Education category, Carlos Rodrigo Gonzalo de Liria, Territorial Clinical Director of Paediatrics and President of Amics de Can Ruti, has been recognised for his contributions. In the Humanities, Cooperation, and Management category, Cristina Vilaplana, a specialist in Microbiology and Parasitology and head of the Experimental Tuberculosis Unit (UTE) at the Germans Trias i Pujol Research Institute (IGTP), has received a well-deserved honour. Finally, in the category of Hospital-Based Medical Care, Elisabet Zamora, head of the Cardiology Hospitalisation Unit, has been recognised for her exemplary service. The award ceremony will take place on 25 November 2024 at 19:00 at the L'illa Auditorium, Av. Diagonal, 547, Barcelona. Congratulations to them all for their dedication and outstanding achievements. Learn more: https://lnkd.in/du7-udJu

🆕 Discovery of a potential molecular mechanism to reduce cardiovascular risk in 6 genetic regions through the metabolites they regulate A team of researchers from Institut d'Investigació Biomèdica de Girona (IDIBGI), Bellvitge Biomedical Research Institute - IDIBELL, IRB Barcelona, Catalan Institute of Oncology and Germans Trias i Pujol Research Institute (IGTP) have identified a potential molecular mechanism by which six genetic loci (genetic regions) are associated with cardiovascular risk through the metabolites they regulate. The results have been published in the journal Genome Medicine. 🗣️ de Cid Rafael, strategic project leader of IGTP's GCAT - Genomes for life and corresponding author of the study, explains: "These findings not only deepen our understanding of the underlying mechanisms of cardiovascular risk but also suggest new targets for drug development". He adds that "regulating blood metabolite levels by modulating gene expression could offer a new pathway to reduce cardiovascular events in high-risk populations". Read more: https://lnkd.in/dChDWUrX #Research #CardiovascularDiseases #GeneticTargets #Genetics

A study conducted by Idibell in collaboration with the Urology Service of the Bellvitge University Hospital, the Andrology Service of the Puigvert Foundation and the High Content Genomics and Bioinformatics Unit of the Germans Trias i Pujol Research Institute (IGTP) - Lauro Sumoy, Jose Francisco Sanchez Herrero:

🆕 ICS 2024 Career Achievement Award and Best Research Poster at the 15th ICS Conference, focused on respiratory diseases We are pleased to announce that Manel Puig Domingo, leader of the Endocrinology and Obesity research group and former director of the Germans Trias i Pujol Research Institute (IGTP) from 2013 to 2020, has been awarded the ICS 2024 Career Achievement Award for Hospitals, and Carlos Mateos, from the Cancer Genetics and Epigenetics research group, has won the Best Research Poster Award. We would also like to congratulate the Institut Català de la Salut and the Institut d'Investigació Biomèdica de Girona (IDIBGI) for organising the conference, and for its commitment to supporting research. Advanced therapies and precision medicine, artificial intelligence applied to respiratory diseases, the importance of networking, and the challenges of social care and ageing in the field of research were some of the topics discussed during the 15th ICS Research Conference. Learn more: https://lnkd.in/dh2HwC4V #ICSResearchAwards #BiomedicalExcellence #RecercaICS #PremisRecercaICS

🆕 The development of a gene therapy for Friedreich’s ataxia receives €2.17 million in new public funding The Ministry of Science and Innovation of Spain has granted €1.7 million and the European Commission an additional €466,000, to support the development of a gene therapy for Friedreich's ataxia by BIOINTAXIS, a spin-off from Germans Trias i Pujol Research Institute (IGTP). Biointaxis is collaborating with IGTP itself and the research institutes of Hospital Universitario La Paz (Fundación para la Investigación Biomédica HULP) and Hospital Universitari de Girona Dr. Josep Trueta - Atenció Primària ICS Girona (Institut d'Investigació Biomèdica de Girona (IDIBGI)) to bring the therapy to a cohort of patients, including paediatric patients. 🗣️ "The financial support from the Spanish Ministry will allow us to consolidate the drug's development and prepare its transition to clinical trials in patients. I am confident that we will begin the clinical trial in 2026", states Antoni Matilla Dueñas, leader of the Neurogenetics research group at IGTP and CEO of Biointaxis. Read more: https://lnkd.in/dAcMUat4 #FriedreichAtaxia #Research #GeneTherapy

🔬 Translational Cancer Research Program (CARE) II Workshop: A Hub for research and collaboration Launched just over two years ago, the CARE program has become a key element in Germans Trias i Pujol Research Institute (IGTP)'s scientific structure. This cross-cutting initiative not only brings together several of our research groups, but also includes researchers from other institutions on the Can Ruti Campus. Last week, over 70 researchers participated in the second CARE workshop, a pivotal event for sharing the latest advancements in cancer research and fostering collaboration. This event was essential in strengthening connections and aligning the community for the future strategic planning of the CARE program. The workshop highlights the importance of collaboration in advancing cancer research and sets the stage for continued progress: https://lnkd.in/dmczRtzX #CancerResearch #CAREprogram

🆕 Grupo Menarini España and the Germans Trias i Pujol Research Institute (IGTP) have signed an agreement which encompasses two projects focusing on severe infections and antibiotic resistance. Both studies were presented within the framework of the "Scientific exchanges: join us" program, a series of internal meetings showcasing Menarini's scientific collaborations. Dr Mª Lluïsa Pedro-Botet, Roger Cortès Tarragó, Dr Noemí Párraga, and Dr Esteban Reynaga, researchers from the Clinical and Environmental Infectious Diseases (CEID) group at IGTP and Hospital Universitari Germans Trias i Pujol, explained the objectives of their projects. 🗣️ Jordi Barretina, general director of IGTP, states that this agreement with Menarini "strengthens our commitment to excellent research in key areas such as severe infections and antibiotic resistance. This public-private collaboration provides us with a valuable opportunity to continue advancing in the fight against global health challenges". Read more: https://lnkd.in/dDeXQT5M #Research #InfectiousDiseases #Legionella #AntibioticResistance

🆕 A new study reveals a promising therapy using a molecule that blocks microRNAs to treat myotonic dystrophy type 1 Researchers from INCLIVA Instituto de Investigación Sanitaria-University of Valencia, led by Dr Ruben Artero, in collaboration with ARTHEx Biotech, Germans Trias i Pujol Research Institute (IGTP), Biogipuzkoa and Medical Research Institute La Fe (IIS La Fe), have identified a therapy based on antimiRs to treat myotonic dystrophy type 1 (DM1). The results of their research have just been published in the journal Science Advances. 🗣️ Dr Gisela Nogales Gadea, leader of the Badalona Neuromuscular Research Group (GRENBA) at IGTP and author of the study, explains: "Thanks to the collaboration of patients in this work, several cell models derived from them have been studied, showing that antimiRs could have therapeutic potential in patients with different degrees of DM1 severity". Read more: https://lnkd.in/dKcCuBg2 #Research #MyotonicDystrophyType1 #DM1